Skip to nav Skip to content
Facebook Twitter LinkedIn Email

New Release 

IDSA HIVMA Joint Logo Updated.png



Remdesivir Distribution to States is a Step in the Right Direction but Transparency Remains Paramount

The U.S. Department of Health and Human Services decision allowing state health departments to distribute limited supplies of remdesivir to treat COVID-19 where they are needed will support fair and equitable access to the drug. The decision, on the use of a Gilead donation to the U.S. of approximately 78,000 treatment courses that followed emergency authorization of the drug to treat the coronavirus, represents a welcome change of course.

Remaining allotments of the drug should be distributed quickly as parts of the country prepare for a peak in infections within the coming weeks. Full and immediate transparency on allocations will be essential for re-opening plans to be informed by available resources.

Data on remdesivir from the Adaptive COVID-19 Treatment Trial should be released now to help hospitals and frontline providers determine which patients may benefit the most from the drug while it remains in limited supply. Federal leadership, transparency and decisions based on evidence will continue to be essential to containing the harmful impacts of this national crisis.  

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.